Indicación terapéutica: Inhibidor de la bomba de protones (IBP) que proporciona una reducción marcada y duradera de la producción de ácido gástrico, tomando como referencia Losec®/AstraZeneca.
Forma farmacéutica: Cápsula gastrorresistente, destinado a la vía de administración indicada en la etiqueta.
Condiciones de almacenamiento: Conservar por debajo de 25 °C, en un lugar seco, protegido de la luz solar directa, en el envase original bien cerrado.

Otra información

Descripción adicional:

Available as 20 mg and 40 mg gastro-resistant omeprazole capsules, referencing Losec®/AstraZeneca. Omeprazole belongs to the proton-pump inhibitor (PPI) class, which markedly and durably reduces stomach acid production; PPIs' potent acid-suppressing effect supports approval for numerous indications, including short-term management of GERD, erosive esophagitis, H. pylori, and duodenal and gastric ulcers, as well as long-term use for NSAID-associated gastric ulcers, hypersecretory conditions, and maintaining healed erosive esophagitis. An EU CTD dossier is available, with stability studies for Zone II/IVb, shelf life of 24 months (20 mg) and 36 months (40 mg), batch sizes of 213,675 capsules (20 mg) and 100,000 capsules (40 mg), and packs of 14 and 28 capsules.